NCT06921408Not yet recruiting
Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
Retrospective Identification of Scintigraphic Cardiac Amyloidosis Using Deep Learning-based Model
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
This study aims to determine the positive predictive value of incidental cardiac uptake on bone scintigraphy for diagnosing transthyretin cardiac amyloidosis, in patients who underwent scintigraphy for reasons other than suspected amyloidosis. The study is an observational, descriptive, multicenter, national study using retrospective data from routine care. Patients with incidental cardiac uptake will be recalled for further diagnostic assessment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 57 (estimated)
- First submitted
- 3 Apr 2025
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- University Hospital, Lille
- Diseases
- Amyloidosis
- NCT number
- NCT06921408
What you commit to
- Study type: Observational
- Planned participants: 57
- From 1 Sept 2026 to the primary completion date, 1 Jul 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients under legal protection
- Patients refusing the reuse of their data after individual information
Who the study is looking for
- Adults (≥ 18 years)
- Patients who underwent bone scintigraphy with 99mTc-HMDP/DPD/PYP for any indication
- Incidental cardiac uptake (Perugini grade ≥2) confirmed by a nuclear medicine specialist
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.